Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-27

.... but understandable. While the scientists at Hopper's companies work hard and achieve amazing results he does whatever he can to devalue them.

Getting funds organised via CR is ok but not at a huge discount. He could have raised at 4c, there is enough money out there, especially considering the CHM 1101 readout and its place in the GBM space. He could have taken the time to get his finance-gurus at IMU to explore overseas markets but using his Bell Potter mates is easier and again, as an assumption, will get him above 51% when taking up the expected shortfall.

RAD is his latest piece of work and here at CHM he signaled to the market that he values it not more than 10m, cash not considered.

Markets often overshoot to either direction but over time find a fair value. But when the top guy intervenes to the downside instead to the upside we get what we've got. Today IMU just shows us how hard it is to get out of this mess having made such a great announcement and yet can't get away from its low sp level. Once down there it becomes almost impossible to recover when the chairman himself kicked it down the drain.

GLTA